KPMA predicted positive list system unlikely successful.

Published: 2006-05-30 06:58:00

Updated: 2006-05-30 06:58:00

The Pharmaceutical Management Analysis Task Force Team (T/F) of the KPMA said in the 2nd quarter meeting after reviewing the recent pharmaceutical environment changes of the KORUS FTA, the NHI drug pricing policy called "Positive List System" and the industry M&A movement that the future FTA nego...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK